article thumbnail

Toregem BioPharma and WuXi Biologics to partner for antibody development

Pharmaceutical Technology

As part of the collaboration, Toregem will use WuXi Biologics’ integrated CMC services in cell culture development, cell line development, bioassay development, biologics GMP manufacturing, cell banking and testing services, as well as other related services.

Antibody 130
article thumbnail

Using analytics and bioassays to de-risk your mRNA LNP drug development programme

Pharmaceutical Technology

But the mRNA technology is not yet mature and there are no standardised manufacturing protocols yet. Some of the variables include the chemical composition of the LNP, the manufacturing process and of course the RNA itself, whose design and production must elicit the intended therapeutic outcome.” weight abundance.

Bioassay 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gene Therapy Comparability

pharmaphorum

The inaugural Gene Therapy Comparability Summit is the only industry dedicated meeting to ensuring your manufacturing processes are effective and comparable at every stage of development, supporting a seamless transition to the larger scales required for commercialization. The post Gene Therapy Comparability appeared first on.

article thumbnail

At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector

Roots Analysis

At-home Self-testing Kit Manufacturers – Current Market Landscape. Cell and Gene Therapy Bioassay Services Market, 2021-2030. Currently, more than 650 at-home self-testing kits are available worldwide and are approved by regulatory authorities. Gene Editing beyond CRISPR Market, 2022-2035. Our Social Media Platform.

article thumbnail

Addressing the challenge of salt forms in drug discovery

Drug Discovery World

These can have better properties than their parents, including preferable stability, solubility, bioavailability, and manufacturability. millimolar solution for a bioassay or a milligram amount of a reactant for a synthesizer could have detrimental skewing effects on a derived dose response curve or could lead to an unbalanced reaction.

Drugs 52
article thumbnail

Reflecting on PEGS Europe 2023 

Drug Discovery World

Protein process development In the protein purification session, Anis Larbi, Senior Manager Medical & Scientific Affairs, Beckman Coulter Life Sciences, presented on reducing the complexity of protein manufacturing and streamlining the workflow.

article thumbnail

Accelerating NDA filing through faster carcinogenicity assessment

Drug Discovery World

Drug discovery and development New pharmaceutical small molecule drugs require extensive safety testing before the manufacturer can obtain regulatory approval for use in humans. Carcinogenicity testing For decades, the two-year rodent bioassay has been the regulatory standard used to determine the carcinogenic potential of new drugs.